Sec. 3. Prescription drug monitoring program requirements
498 words·~2 min read·
/bill/115/s/778/is/section-3A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Beginning 2 years after the date of enactment of this Act, each covered State shall require— each prescribing practitioner within the covered State or their designee, who shall be licensed or registered healthcare professionals or other employees who report directly to the practitioner, to consult the PDMP of the covered State before initiating treatment with a prescription for a controlled substance listed in schedule II, III, or IV of section 202(c) of the Controlled Substances Act ( 21 U.S.C. 812(c) ), and every 3 months thereafter as long as the treatment continues; the PDMP of the covered State to provide proactive notification to a practitioner when patterns indicative of controlled substance misuse, including opioid misuse, are detected; each dispenser within the covered State to report each prescription for a controlled substance dispensed by the dispenser to the PDMP not later than 24 hours after the controlled substance is dispensed to the patient; that the PDMP make available a quarterly de-identified data set and an annual report for public and private use, which shall, at a minimum, meet requirements established by the Attorney General, in coordination with the Secretary of Health and Human Services; and that the data contained in the PDMP of the covered State is made available to other States.
If a covered State fails to comply with subsection (a), the Attorney General or the Secretary of Health and Human Services, as appropriate, may withhold grant funds from being awarded to the covered State under the Harold Rogers Prescription Drug Monitoring Program established under the Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 2002 ( Public Law 107–77 ; 115 Stat. 748) or the controlled substance monitoring program under section 399O of the Public Health Service Act ( 42 U.S.C. 280g–3 ).
For the purpose of assisting States in complying with subsection (a)(5), the Attorney General, in coordination with the Secretary of Health and Human Services, acting through the Comprehensive Opioid Abuse Grant Program established under section 3021 of title I of the Omnibus Crime Control and Safe Streets Act of 1968 ( 42 U.S.C. 3797ff ), shall award, on a competitive basis, a grant to an eligible entity to establish and maintain an inter-State data-sharing single hub to facilitate the sharing of PDMP data among States and the accessing of such data by practitioners.
The data-sharing single hub established under paragraph (1)— shall— allow States to retain ownership of the data submitted by the States; provide a source of de-identified data that can be used for statistical, research, or educational purposes; allow State authorized users to access data from a PDMP of a covered State without requiring a user fee; and conform with the standards of the Prescription Monitoring Information Exchange; and may not— distribute, in whole or in part, any PDMP data without the express written consent of the PDMP State authority; and limit, in whole or in part, distribution of PDMP data as approved by the PDMP State authority.
Connectionstraces to 2
Traces to 2 documents
3 references not yet in our index
- Pub. L. 107-77
- 115 Stat. 748
- 42 USC 280g–3
Citation graph
cites case law
Sec. 3
Prescription drug monitoring program requirements
Pub. L.Pub. L. 107-77
Stat.115 Stat. 748
Cite42 USC 280g–3
Cites 5Cited by 0 across 0 sources